Joshua A. Beckman, MD. Brigham and Women s Hospital

Similar documents
The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

Cath Lab Essentials : Peripheral Vascular Disease in Patients with CAD

STATINS FOR PAD Long - term prognosis

When to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht

Carotid Artery Disease How the Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Early Identification of PAD: Evidence to Refute USPSTF Position on Screening

ACC NY Cardiovascular Symposium

What s New in the Management of Peripheral Arterial Disease

VDF and The Burden of Vascular Disease

Introduction. Risk factors of PVD 5/8/2017

Larry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI

7 th Munich Vascular Conference

Goals of Screening Programs. What is Vascular Screening? Assumptions Regarding the Potential Benefits of Screening Programs PAD

How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention

Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options

BEST OF Groupe Vasculaire Thrombose

A new era in the treatment of peripheral artery disease (PAD)?

John E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division

Is there an association between atherosclerosis and chronic venous disease?

Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million life insurance

Case Study: Chris Arden. Peripheral Arterial Disease

CVD risk assessment using risk scores in primary and secondary prevention

- Lecture - Recommandations ESC : messages importants P. MEYER (Saint Laurent du Var) - Controverse - Qui doit faire l'angioplastie périphérique?

Introduction to Peripheral Artery Disease. Dr. Tee Chee Hian

Guidelines for Management of Peripheral Arterial Disease

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million Life Insurance

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

The Struggle to Manage Stroke, Aneurysm and PAD

The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered?

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

Carotid Ddisease, Carotid IMT and Risk of Stroke

Current and Future Imaging Trends in Risk Stratification for CAD

PERIPHERAL ARTERIAL DISEASE (PAD); Frequency in diabetics.

Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery

The presenter does not have any potential conflicts of interest to disclose

CardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai

Is there enough evidence for DAPT after endovascular intervention for PAOD?

New Paradigms in Predicting CVD Risk

New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008

Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis

1. Which one of the following patients does not need to be screened for hyperlipidemia:

How would you manage Ms. Gold

Carotid Artery Stenosis

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?

Peripheral Arterial Disease: Objectives. Disclosure. Definition: Peripheral Arterial Disease (PAD)

Causes of death in Diabetes

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

AAIM TRIENNIAL COURSE 124 TH ANNUAL MEETING. The Broadmoor Colorado Springs, CO

Antiplatelet agents treatment

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

Carotid Artery Stenting

Medical Therapy for Peripheral Artery Disease

Hidden coronary disease in carotid patients

National Clinical Conference 2018 Baltimore, MD

DECLARATION OF CONFLICT OF. No conflict INTEREST

Which Patients Are Good Candidates for Carotid Artery Stenting or Carotid Endarterectomy

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Surgery for patients with diffuse atherosclerotic disease

Guidelines for Ultrasound Surveillance

Can We Cure Atherosclerosis?

ESC Heart & Brain Workshop

Prevention of MACROvascular Complications of Diabetes

PAR-1 Antagonist: What Do Clinical Trials Teach Us?

SAVE LIMBS SAVE LIVES!

Peripheral Arterial Disease Extremity

PCSK9 Inhibitors and Modulators

Vascular Protection in Patients with CAD and PAD: New Options

Lnformation Coverage Guidance

Carotid Artery Stenting Versus

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Medical Management of Vascular Disease KEITH E SWANSON MD ND ACADEMY OF FAMILY PHYSICIANS FAMILY MEDICINE UPDATE JANUARY 2017

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Supplementary Online Content

PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016

Update on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Carotid Artery Stent: Is it ready for prime time?

Co chce/čeká neurochirug od anesteziologa během karotické endarterektomie?

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

USWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential

The TNT Trial Is It Time to Shift Our Goals in Clinical

Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease

Registry Assessment of Peripheral Interventional Devices (RAPID)

Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment

Surveillance of Peripheral Arterial Disease Cases Using Natural Language Processing of Clinical Notes

Atherothrombosis And Coronary Artery Disease

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

TCD in Subclavian Steal Syndrome

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic

NON-CORONARY ARTERIAL DISEASE

Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery

10/17/16. Assessing cardiovascular risk through use of inflammation testing

The Clinical Unmet need in the patient with Diabetes and ACS

Overview of Subclavian & Innominate Artery Interventions

Transcription:

Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham and Women s Hospital

Agenda Discuss the concept that atherosclerosis is a systemic disease PAD Carotid disease Renal artery stenosis

Atherosclerosis A Progressive Disease Atherosclerosis Thrombosis Stable angina/intermittent claudication Unstable angina MI Ischemic stroke/tia Critical leg ischemia Intermittent claudication CV death ACS Adapted from Libby P. Circulation. 2001;104:365-372

Definition of Peripheral Artery Disease (PAD) The presence of a stenosis or occlusion in the aorta or arteries of the limbs One of the three cardinal manifestations of atherosclerosis in addition to CAD & CVD. Associated with an increased risk of cardiovascular and cerebrovascular events, including death, MI, and stroke

Prevalence of PAD NHANES 1 Aged >40 years San Diego 2 Mean age 66 years NHANES 1 Aged 70 years Rotterdam 3 Aged >55 years Diehm 4 Aged 65 years 4.3% 11.7% 14.5% PARTNERS 5 Aged >70 years, or 50 69 years with a history diabetes or smoking 19.1% 19.8% In a primary care population defined by age and common risk factors, the prevalence of PAD was approximately one in three patients 29% 0% 5% 10% 15% 20% 25% 30% 35% NHANES=National Health and Nutrition Examination Study; PARTNERS=PAD Awareness, Risk, and Treatment: New Resources for Survival [program]. 1. Selvin E, Erlinger TP. Circulation. 2004;110:738-743. 2. Criqui MH et al. Circulation. 1985;71:510-515. 3. Diehm C et al. Atherosclerosis. 2004;172:95-105. 4. Meijer WT et al. Arterioscler Thromb Vasc Biol. 1998;18:185-192. 5. Hirsch AT et al. JAMA. 2001;286:1317-1324.

Risk Factors for PAD Reduced Increased Smoking Diabetes Hypertension Hypercholesterolemia Hyperhomocysteinemia C-Reactive Protein Relative Risk 0 1 2 3 4 5 6 Hirsch AT, et al. J Am Coll Cardiol. 2006;47:e1-e192.

PARTNERS: Prevalence of PAD and CVD in Primary Care Practices 29% of Patients Were Diagnosed With PAD Using ABI 29% 44% 56% Patients diagnosed with PAD PAD only PAD and CVD ABI=ankle-brachial index; CAD=coronary artery disease; CVD=cardiovascular disease. Hirsch AT et al. JAMA. 2001;286:1317-1324.

Long-term Survival in Patients With PAD 100 Survival (%) 75 50 25 Normal subjects Asymptomatic PAD Symptomatic PAD Severe symptomatic PAD 0 2 4 6 8 10 12 Year Criqui MH et al. N Engl J Med. 1992;326:381-386.

Contemporary PAD Rates of Myocardial Infarction and Death 3649 subjects (average age 64 yrs) followed up for 7.2 years % Hooi JD, et al. J Clin Epid. 2004;57:294 300.

Diehm, C. et al. Circulation 2009;120:2053-2061 Event-Free Survival by PAD Status at 5 Years in 2009 Prospective cohort of 6880 unselected patients >65 years of age with follow-up for 5 years. 5392 pts had no PAD, 836 had asx PAD and 593 had symptomatic PAD

Diabetes Increases Risk of Adverse Outcome Among PAD Patients N=136 Patients with PAD undergoing LE Angio Follow-up 4.5 Years OR=5.4 OR=3.1 Jude EB, et al., Diabetes Care. 2001;24:1433.

Atherothrombosis & Life Expectancy: Framingham Heart Study In the FHS, healthy individuals aged 60 years who did not have atherothrombosis were expected to live a further 20 years to the age of 80 Comparatively, patients with a history of MI lived 9.2 fewer years Those with a history of CVA lived 12 fewer years Life Expectancy (Years) 20 15 10 5 20 9.2 Fewer years 12 Fewer years 0 Healthy History of MI History of CVA Bakhai A. Pharmacoeconomics 2004; 22(suppl 4): 11-18

Proportion of ischemic stroke subtypes: NOMASS White, H. Circ 2005;111:1327

Current Event Rates In Patients with Asymptomatic Carotid Stenosis 2684 consecutive patients with arterial disease or type 2 DM, but without a history of cerebral ischemia, with a mean follow up of 3.6 years Goessens, BMB. Stroke. 2007;38:1470-1475

Mayo Clinic Asymptomatic Carotid Endarterectomy (MACE) Study % Mayo Asymptomatic Carotid Endarterectomy Study Group. Mayo Clin Proc. 1992;67:513 518.

Carotid Bruits Predict Cardiovascular Death Better Than Stroke Pickett, CA. Lancet 2008; 371: 1587

Causes of Death in ACAS at 5 Years ACST-Outcome Related Mortality Both Groups Immediate CEA Deferral Perioperative 4 3 1 Non-perioperative stroke 5 2 3 Other mortality MI or Cardiac 84 36 48 Respiratory 19 10 9 Neoplastic 28 15 13 ACAS Executive Committee JAMA 1995; 273(18): 1421 4

Causes of Death in ACST at 10 Years ACST-Outcome Related Mortality Both Groups Immediate CEA Deferral Logrank p- value Perioperative 20 17 3 0.002 Non-perioperative stroke Other mortality 107 39 68 0.006 Vascular 565 298 267 0.15 Neoplastic 212 111 101 0.44 Other 276 145 131 0.33 Halliday, A Lancet 2010; 376: 1074 84

Even Medical Therapy for Carotid Disease Works Better for CAD Heart Protection Study Results Vascular Simvastatin Placebo Net difference Coronary 587 (5.7%) 707 (6.9) 120 Other Vascular 194 (1.9%) 230 (2.2%) 36 Non-Vascular Neoplastic 359 (3.5%) 345 (3.4%) 14 Respiratory 90 (0.9%) 114 (1.1) 8 HPS Study Group. Lancet 2002;360:7-22

Blood Pressure Lowering Agents Improve CHD Outcomes More Than Stroke Outcomes HOPE Study Results Vascular Rampril Placebo Net difference CV Death 282 (6.1%) 377 (8.1%) 95 MI 459 (9.9%) 570 (12.3%) 111 Stroke 156 (3.4%) 226 (4.9%) 70 Death 482 (10.4%) 569 (12.2%) 87 HPS Study Group. Lancet 2002;360:7-22

Renal and Cardiovascular Events in ASTRAL N. Engl.J.Med: 361: 1953-1962, 2009

Mortality in Patients With ARVD Retrospective analysis of records from patients who underwent renal arterial interventions, endovascular or open bypass, between January 1984 and January 2004. Ann Vasc Surg 2005; 19:218-228

Aboyans, V. JACC 2007; 49(14): 1540-5 By The Way, It s Every Vascular Bed! Baseline and follow-up data (mean 9.8 years) were complete in 1,778 participants. Subclavian stenosis was found in 157 (8.8%) subjects.

Summary Atherosclerosis is a systemic disease The rates of cardiovascular morbidity and mortality are always higher than the specific arterial bed involved If you discover atherosclerosis anywhere, know it is everywhere, and needs aggressive medical treatment.